Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2019-02-12 Merger & Acquisition
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933 and relates to the combination (merger) of Mereo BioPharma Group plc and OncoMed Pharmaceuticals, Inc. It includes detailed information about the transaction terms, management and governance of the combined company, strategic rationale, and updates on the transaction process. It references filings such as the Form F-4 registration statement and proxy statement/prospectus related to the merger. The content is focused on merger-related disclosures and solicitation of proxies for shareholder approval. There is no indication that this is a full annual report, earnings release, or other financial report. The document is a communication related to a merger transaction under Rule 425, which is used for merger communications and proxy solicitation materials. Therefore, the appropriate classification is Merger & Acquisition (MA).
2019-02-12 English
Board Change
Board/Management Information Classification · 100% confidence The document is an official announcement from Mereo BioPharma Group plc regarding the resignation of a non-executive director and the planned appointment of new directors. This falls directly under the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. While it is distributed via RNS (Regulatory News Service), the specific content is a board change notification, making MANG the most precise classification.
2019-02-11 English
Publication of F-4
M&A Activity Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement issued by Mereo BioPharma Group plc. It serves as a formal notification to the market that the company has filed a preliminary registration statement on Form F-4 with the U.S. SEC regarding a proposed merger/combination with OncoMed Pharmaceuticals. The text explicitly states it is an announcement of a filing, provides context for the transaction, and directs readers to where they can access the actual Form F-4 document. Per the 'Menu vs Meal' rule, this is an announcement of a report/filing rather than the filing itself, and it fits the definition of a Report Publication Announcement (RPA).
2019-01-25 English
Regulatory Filings 2019
Regulatory Filings Classification · 100% confidence The document is a Pre-Effective Amendment No. 2 to Registration Statement on Form F-6 filed with the SEC. Form F-6 is used for the registration of American Depositary Shares (ADSs) evidenced by American Depositary Receipts (ADRs). The document includes details about the deposit agreement, the securities to be registered, and signatures of company officers and depositary representatives. It is a regulatory filing related to securities registration rather than a financial report, earnings release, or management discussion. The document is not an annual report, interim report, or any other financial statement but a registration statement amendment. Therefore, it fits best under Regulatory Filings (RNS). The document length is 13,369 characters, indicating it is a full filing, not a brief announcement.
2019-01-25 English
F-4
Merger & Acquisition Classification · 100% confidence The document is a Form F-4 Registration Statement filed with the SEC, which is used for securities registration in connection with mergers and acquisitions. It includes detailed information about a merger proposal, voting instructions for stockholders, and proxy statement/prospectus content. The presence of merger agreement details, proxy solicitation, and voting proposals indicates this is related to a merger transaction filing. The Form F-4 is specifically used for merger-related securities registration and proxy solicitation. Therefore, this document fits the category of Merger & Acquisition filings (MA). The document length and content confirm it is the filing itself, not just an announcement or summary.
2019-01-25 English
New Deferred Bonus Plan
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Mereo BioPharma Group plc regarding the approval of a new deferred bonus plan for executive directors and senior management. While it discusses remuneration policy, it is not a formal proxy statement (DEF 14A) but rather a corporate announcement of a new internal policy. Since it does not fit into specific categories like 'Director's Dealing' (no specific trade reported) or 'Remuneration Information' (which typically refers to the detailed annual compensation report), it is best classified as a general regulatory announcement.
2019-01-18 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.